Do analysts recommend SKYE or GELS?

Skye Bioscience presently has a consensus target price of $8.50, indicating a potential upside of 1,113.42%. Given Skye Bioscience's stronger consensus rating and higher probable upside, equities research analysts plainly believe Skye Bioscience is more favorable than Gelteq. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, SKYE or GELS?

Gelteq has higher revenue and earnings than Skye Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Skye Bioscience N/A N/A -$55.92M -$1.44 N/A Gelteq $110K 56.44 -$4.30M N/A N/A

Is SKYE or GELS more profitable?

Gelteq's return on equity of 0.00% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -217.27% -162.39% Gelteq N/A N/A N/A

Does the media favor SKYE or GELS?

In the previous week, Gelteq had 2 more articles in the media than Skye Bioscience. MarketBeat recorded 3 mentions for Gelteq and 1 mentions for Skye Bioscience. Gelteq's average media sentiment score of 0.36 beat Skye Bioscience's score of 0.00 indicating that Gelteq is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gelteq 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate GELS or MRKR?

Marker Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 580.27%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than Gelteq. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Marker Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger earnings & valuation, GELS or MRKR?

Gelteq has higher earnings, but lower revenue than Marker Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 56.44 -$4.30M N/A N/A Marker Therapeutics $3.55M 6.90 -$12.16M -$0.61 N/A

Does the media refer more to GELS or MRKR?

In the previous week, Gelteq had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for Gelteq and 1 mentions for Marker Therapeutics. Gelteq's average media sentiment score of 0.36 beat Marker Therapeutics' score of 0.00 indicating that Gelteq is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gelteq 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Marker Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer GELS or TXMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, GELS or TXMD?

TherapeuticsMD has higher revenue and earnings than Gelteq. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 56.44 -$4.30M N/A N/A TherapeuticsMD $3.02M 8.08 -$570K $0.06 35.17

Do analysts recommend GELS or TVGN?

Tevogen Bio has a consensus price target of $100.00, suggesting a potential upside of 1,633.10%. Given Tevogen Bio's stronger consensus rating and higher probable upside, analysts plainly believe Tevogen Bio is more favorable than Gelteq. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher earnings & valuation, GELS or TVGN?

Gelteq has higher revenue and earnings than Tevogen Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 56.44 -$4.30M N/A N/A Tevogen Bio N/A N/A -$26.27M -$4.61 N/A

Is GELS or TVGN more profitable?

Company Net Margins Return on Equity Return on Assets Gelteq N/A N/A N/A Tevogen Bio N/A N/A -472.77%

Does the media prefer GELS or TVGN?

In the previous week, Gelteq had 2 more articles in the media than Tevogen Bio. MarketBeat recorded 3 mentions for Gelteq and 1 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 0.67 beat Gelteq's score of 0.36 indicating that Tevogen Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gelteq 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Tevogen Bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ALVR or GELS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, ALVR or GELS?

Gelteq has higher revenue and earnings than AlloVir. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Gelteq $110K 56.44 -$4.30M N/A N/A

Is ALVR or GELS more profitable?

Gelteq's return on equity of 0.00% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Gelteq N/A N/A N/A

Gelteq (GELS) Competitors

$0.58 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$0.58 0.00 (-0.12%)

As of 07/2/2026 07:34 PM Eastern

Compare

GELS vs. SKYE, MRKR, TXMD, TVGN, and ALVR

Should you buy Gelteq stock or one of its competitors? MarketBeat compares Gelteq with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gelteq include Skye Bioscience (SKYE), Marker Therapeutics (MRKR), TherapeuticsMD (TXMD), Tevogen Bio (TVGN), and AlloVir (ALVR). These companies are all part of the "pharmaceutical products" industry.

How does Gelteq compare to Skye Bioscience?

Skye Bioscience (NASDAQ:SKYE) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Gelteq's return on equity of 0.00% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
Gelteq	N/A	N/A	N/A

Skye Bioscience has a beta of 2.94, suggesting that its share price is 194% more volatile than the broader market. Comparatively, Gelteq has a beta of -0.55, suggesting that its share price is 155% less volatile than the broader market.

Gelteq has higher revenue and earnings than Skye Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
Gelteq	$110K	56.44	-$4.30M	N/A	N/A

Skye Bioscience presently has a consensus target price of $8.50, indicating a potential upside of 1,113.42%. Given Skye Bioscience's stronger consensus rating and higher probable upside, equities research analysts plainly believe Skye Bioscience is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Gelteq had 2 more articles in the media than Skye Bioscience. MarketBeat recorded 3 mentions for Gelteq and 1 mentions for Skye Bioscience. Gelteq's average media sentiment score of 0.36 beat Skye Bioscience's score of 0.00 indicating that Gelteq is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Skye Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gelteq	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

21.1% of Skye Bioscience shares are owned by institutional investors. 6.2% of Skye Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Skye Bioscience beats Gelteq on 7 of the 13 factors compared between the two stocks.

How does Gelteq compare to Marker Therapeutics?

Gelteq (NASDAQ:GELS) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

22.4% of Marker Therapeutics shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Gelteq has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Gelteq's return on equity of 0.00% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
Marker Therapeutics	-343.03%	-73.29%	-59.70%

Marker Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 580.27%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Gelteq has a beta of -0.55, indicating that its stock price is 155% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

In the previous week, Gelteq had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for Gelteq and 1 mentions for Marker Therapeutics. Gelteq's average media sentiment score of 0.36 beat Marker Therapeutics' score of 0.00 indicating that Gelteq is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gelteq	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Marker Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gelteq has higher earnings, but lower revenue than Marker Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	56.44	-$4.30M	N/A	N/A
Marker Therapeutics	$3.55M	6.90	-$12.16M	-$0.61	N/A

Summary

Gelteq and Marker Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Gelteq compare to TherapeuticsMD?

Gelteq (NASDAQ:GELS) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

TherapeuticsMD has higher revenue and earnings than Gelteq.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	56.44	-$4.30M	N/A	N/A
TherapeuticsMD	$3.02M	8.08	-$570K	$0.06	35.17

TherapeuticsMD has a net margin of 5.34% compared to Gelteq's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Gelteq's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
TherapeuticsMD	5.34%	0.32%	0.23%

Gelteq has a beta of -0.55, meaning that its share price is 155% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

30.7% of TherapeuticsMD shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Gelteq had 3 more articles in the media than TherapeuticsMD. MarketBeat recorded 3 mentions for Gelteq and 0 mentions for TherapeuticsMD. Gelteq's average media sentiment score of 0.36 beat TherapeuticsMD's score of 0.00 indicating that Gelteq is being referred to more favorably in the media.

Company	Overall Sentiment
Gelteq	Neutral
TherapeuticsMD	Neutral

Summary

TherapeuticsMD beats Gelteq on 8 of the 11 factors compared between the two stocks.

How does Gelteq compare to Tevogen Bio?

Gelteq (NASDAQ:GELS) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Gelteq has a beta of -0.55, suggesting that its share price is 155% less volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Tevogen Bio has a consensus price target of $100.00, suggesting a potential upside of 1,633.10%. Given Tevogen Bio's stronger consensus rating and higher probable upside, analysts plainly believe Tevogen Bio is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
Tevogen Bio	N/A	N/A	-472.77%

Gelteq has higher revenue and earnings than Tevogen Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	56.44	-$4.30M	N/A	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A

In the previous week, Gelteq had 2 more articles in the media than Tevogen Bio. MarketBeat recorded 3 mentions for Gelteq and 1 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 0.67 beat Gelteq's score of 0.36 indicating that Tevogen Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gelteq	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Tevogen Bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Gelteq and Tevogen Bio tied by winning 4 of the 8 factors compared between the two stocks.

How does Gelteq compare to AlloVir?

AlloVir (NASDAQ:ALVR) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

In the previous week, Gelteq had 3 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Gelteq and 0 mentions for AlloVir. Gelteq's average media sentiment score of 0.36 beat AlloVir's score of 0.00 indicating that Gelteq is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
Gelteq	Neutral

Gelteq's return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Gelteq	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Gelteq has higher revenue and earnings than AlloVir.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Gelteq	$110K	56.44	-$4.30M	N/A	N/A

AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Gelteq has a beta of -0.55, indicating that its share price is 155% less volatile than the broader market.

66.1% of AlloVir shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Gelteq beats AlloVir on 7 of the 10 factors compared between the two stocks.

Get Gelteq News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GELS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GELS vs. The Competition

Export

Metric	Gelteq	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.21M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	N/A	21.80	27.78	24.70
Price / Sales	56.44	340.22	540.55	99.42
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	0.54	8.66	10.96	6.46
Net Income	-$4.30M	$23.81M	$3.57B	$337.01M
7 Day Performance	-8.42%	3.39%	2.12%	1.69%
1 Month Performance	16.64%	10.81%	5.25%	3.81%
1 Year Performance	-66.30%	62.61%	33.29%	23.90%

Gelteq Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GELS Gelteq	0.8689 of 5 stars	$0.58 flat	N/A	-66.3%	$6.21M	$110K	N/A	N/A	Earnings Report Gap Up
SKYE Skye Bioscience	2.0022 of 5 stars	$0.70 flat	$8.50 +1,113.4%	-84.7%	$24.62M	N/A	N/A	11
MRKR Marker Therapeutics	1.9564 of 5 stars	$1.47 flat	$10.00 +580.3%	-6.7%	$24.51M	$3.55M	N/A	60	News Coverage
TXMD TherapeuticsMD	0.9851 of 5 stars	$2.11 flat	N/A	+88.4%	$24.42M	$3.02M	35.17	420
TVGN Tevogen Bio	1.9441 of 5 stars	$5.77 flat	$100.00 +1,633.1%	-90.7%	$24.16M	N/A	N/A	3	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GELS) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gelteq (GELS) Competitors

GELS vs. SKYE, MRKR, TXMD, TVGN, and ALVR

How does Gelteq compare to Skye Bioscience?

Summary

How does Gelteq compare to Marker Therapeutics?

Summary

How does Gelteq compare to TherapeuticsMD?

Summary

How does Gelteq compare to Tevogen Bio?

Summary

How does Gelteq compare to AlloVir?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS vs. The Competition

Gelteq Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gelteq (GELS) Competitors

GELS vs. SKYE, MRKR, TXMD, TVGN, and ALVR

How does Gelteq compare to Skye Bioscience?

Is SKYE or GELS more profitable?

Which has more risk & volatility, SKYE or GELS?

Which has higher valuation & earnings, SKYE or GELS?

Do analysts recommend SKYE or GELS?

Does the media favor SKYE or GELS?

Do insiders and institutionals have more ownership in SKYE or GELS?

Summary

How does Gelteq compare to Marker Therapeutics?

Do institutionals & insiders hold more shares of GELS or MRKR?

Is GELS or MRKR more profitable?

Do analysts rate GELS or MRKR?

Which has more risk and volatility, GELS or MRKR?

Does the media refer more to GELS or MRKR?

Which has stronger earnings & valuation, GELS or MRKR?

Summary

How does Gelteq compare to TherapeuticsMD?

Which has higher valuation & earnings, GELS or TXMD?

Is GELS or TXMD more profitable?

Which has more risk and volatility, GELS or TXMD?

Do analysts prefer GELS or TXMD?

Do institutionals and insiders believe in GELS or TXMD?

Does the media favor GELS or TXMD?

Summary

How does Gelteq compare to Tevogen Bio?

Which has more volatility & risk, GELS or TVGN?

Do analysts recommend GELS or TVGN?

Is GELS or TVGN more profitable?

Which has higher earnings & valuation, GELS or TVGN?

Does the media prefer GELS or TVGN?

Summary

How does Gelteq compare to AlloVir?

Does the media refer more to ALVR or GELS?

Is ALVR or GELS more profitable?

Do analysts rate ALVR or GELS?

Which has preferable valuation and earnings, ALVR or GELS?

Which has more volatility & risk, ALVR or GELS?

Do institutionals and insiders believe in ALVR or GELS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS vs. The Competition

Gelteq Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools